Altered Energy Production, Lowered Antioxidant Potential, and Inflammatory Processes Mediate CNS Damage Associated with Abuse of the Psychostimulants MDMA and Methamphetamine

Overview

Journal Eur J Pharmacol

Specialty Pharmacology

Date 2014 Feb 4

PMID 24485894

Citations 10

Authors

Luke A Downey

Jennifer M Loftis

Affiliations

Soon will be listed here.

Abstract

Central nervous system (CNS) damage associated with psychostimulant dependence may be an ongoing, degenerative process with adverse effects on neuropsychiatric function. However, the molecular mechanisms regarding how altered energy regulation affects immune response in the context of substance use disorders are not fully understood. This review summarizes the current evidence regarding the effects of psychostimulant [particularly 3,4-methylenedioxy-N-methylamphetamine (MDMA) and methamphetamine] exposure on brain energy regulation, immune response, and neuropsychiatric function. Importantly, the neuropsychiatric impairments (e.g., cognitive deficits, depression, and anxiety) that persist following abstinence are associated with poorer treatment outcomes - increased relapse rates, lower treatment retention rates, and reduced daily functioning. Qualifying the molecular changes within the CNS according to the exposure and use patterns of specifically abused substances should inform the development of new therapeutic approaches for addiction treatment.

Citing Articles

Exploring amygdala structural changes and signaling pathways in postmortem brains: consequences of long-term methamphetamine addiction.

Azimzadeh Z, Omidvari S, Niknazar S, Vafaei-Nezhad S, Roozbahany N, Abdollahifar M Anat Cell Biol. 2023; 57(1):70-84.

PMID: 37994041 PMC: 10968194. DOI: 10.5115/acb.23.193.

Is Deep Brain Stimulation an Effective Treatment for Psychostimulant Dependency? A Preclinical and Clinical Systematic Review.

Eskandari K, Fattahi M, Yazdanian H, Haghparast A Neurochem Res. 2022; 48(5):1255-1268.

PMID: 36445490 DOI: 10.1007/s11064-022-03818-3.

Association between white matter microstructure and cognitive function in patients with methamphetamine use disorder.

Zhou Y, Hu Y, Wang Q, Yang Z, Li J, Ma Y Hum Brain Mapp. 2022; 44(2):304-314.

PMID: 35838008 PMC: 9842920. DOI: 10.1002/hbm.26020.

Striatal Reinnervation Process after Acute Methamphetamine-Induced Dopaminergic Degeneration in Mice.

Granado N, Ares-Santos S, Tizabi Y, Moratalla R Neurotox Res. 2018; 34(3):627-639.

PMID: 29934756 DOI: 10.1007/s12640-018-9925-z.

Functional connectivity, behavioral and dopaminergic alterations 24 hours following acute exposure to synthetic bath salt drug methylenedioxypyrovalerone.

Colon-Perez L, Pino J, Saha K, Pompilus M, Kaplitz S, Choudhury N Neuropharmacology. 2018; 137:178-193.

PMID: 29729891 PMC: 6397742. DOI: 10.1016/j.neuropharm.2018.04.031.

References

Potula R, Hawkins B, Cenna J, Fan S, Dykstra H, Ramirez S . Methamphetamine causes mitrochondrial oxidative damage in human T lymphocytes leading to functional impairment. J Immunol. 2010; 185(5):2867-76. PMC: 3124898. DOI: 10.4049/jimmunol.0903691. View

Brownlee M, Vlassara H, Cerami A . Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med. 1984; 101(4):527-37. DOI: 10.7326/0003-4819-101-4-527. View

Zuloaga D, Siegel J, Acevedo S, Agam M, Raber J . Developmental methamphetamine exposure results in short- and long-term alterations in hypothalamic-pituitary-adrenal-axis-associated proteins. Dev Neurosci. 2013; 35(4):338-46. PMC: 3845800. DOI: 10.1159/000351278. View

Martinez L, Mihu M, Gacser A, Santambrogio L, Nosanchuk J . Methamphetamine enhances histoplasmosis by immunosuppression of the host. J Infect Dis. 2009; 200(1):131-41. PMC: 11530355. DOI: 10.1086/599328. View

Friend D, Son J, Keefe K, Fricks-Gleason A . Expression and activity of nitric oxide synthase isoforms in methamphetamine-induced striatal dopamine toxicity. J Pharmacol Exp Ther. 2012; 344(2):511-21. PMC: 3558820. DOI: 10.1124/jpet.112.199745. View

Potter A, Downey L, Stough C . Cognitive function in ecstasy naive abstinent drug dependants and MDMA users. Curr Drug Abuse Rev. 2012; 6(1):71-6. DOI: 10.2174/1874473711306010008. View

Chang L, Alicata D, Ernst T, Volkow N . Structural and metabolic brain changes in the striatum associated with methamphetamine abuse. Addiction. 2007; 102 Suppl 1:16-32. DOI: 10.1111/j.1360-0443.2006.01782.x. View

Berman S, Voytek B, Mandelkern M, Hassid B, Isaacson A, Monterosso J . Changes in cerebral glucose metabolism during early abstinence from chronic methamphetamine abuse. Mol Psychiatry. 2007; 13(9):897-908. PMC: 2786221. DOI: 10.1038/sj.mp.4002107. View

Gouzoulis-Mayfrank E, Schreckenberger M, Sabri O, Arning C, Thelen B, Spitzer M . Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG. Neuropsychopharmacology. 1999; 20(6):565-81. DOI: 10.1016/S0893-133X(98)00089-X. View

10.

Sailasuta N, Abulseoud O, Harris K, Ross B . Glial dysfunction in abstinent methamphetamine abusers. J Cereb Blood Flow Metab. 2009; 30(5):950-60. PMC: 2949186. DOI: 10.1038/jcbfm.2009.261. View

11.

Muneer P, Alikunju S, Szlachetka A, Haorah J . Methamphetamine inhibits the glucose uptake by human neurons and astrocytes: stabilization by acetyl-L-carnitine. PLoS One. 2011; 6(4):e19258. PMC: 3083423. DOI: 10.1371/journal.pone.0019258. View

12.

Volkow N, Fowler J, Wang G . The addicted human brain: insights from imaging studies. J Clin Invest. 2003; 111(10):1444-51. PMC: 155054. DOI: 10.1172/JCI18533. View

13.

Kaizaki A, Tanaka S, Tsujikawa K, Numazawa S, Yoshida T . Recreational drugs, 3,4-Methylenedioxymethamphetamine(MDMA), 3,4-methylenedioxyamphetamine (MDA) and diphenylprolinol, inhibit neurite outgrowth in PC12 cells. J Toxicol Sci. 2010; 35(3):375-81. DOI: 10.2131/jts.35.375. View

14.

Cubells J, Rayport S, Rajendran G, Sulzer D . Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J Neurosci. 1994; 14(4):2260-71. PMC: 6577123. View

15.

Urrutia A, Rubio-Araiz A, Gutierrez-Lopez M, ElAli A, Hermann D, OShea E . A study on the effect of JNK inhibitor, SP600125, on the disruption of blood-brain barrier induced by methamphetamine. Neurobiol Dis. 2012; 50:49-58. DOI: 10.1016/j.nbd.2012.10.006. View

16.

Kousik S, Napier T, Carvey P . The effects of psychostimulant drugs on blood brain barrier function and neuroinflammation. Front Pharmacol. 2012; 3:121. PMC: 3386512. DOI: 10.3389/fphar.2012.00121. View

17.

Capela J, Carmo H, Remiao F, Bastos M, Meisel A, Carvalho F . Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Mol Neurobiol. 2009; 39(3):210-71. DOI: 10.1007/s12035-009-8064-1. View

18.

Bosch O, Wagner M, Jessen F, Kuhn K, Joe A, Seifritz E . Verbal memory deficits are correlated with prefrontal hypometabolism in (18)FDG PET of recreational MDMA users. PLoS One. 2013; 8(4):e61234. PMC: 3621736. DOI: 10.1371/journal.pone.0061234. View

19.

Pubill D, Chipana C, Camins A, Pallas M, Camarasa J, Escubedo E . Free radical production induced by methamphetamine in rat striatal synaptosomes. Toxicol Appl Pharmacol. 2005; 204(1):57-68. DOI: 10.1016/j.taap.2004.08.008. View

20.

Permpoonputtana K, Govitrapong P . The anti-inflammatory effect of melatonin on methamphetamine-induced proinflammatory mediators in human neuroblastoma dopamine SH-SY5Y cell lines. Neurotox Res. 2012; 23(2):189-99. DOI: 10.1007/s12640-012-9350-7. View